New drug shows promise against rare eye cancer before liver surgery
NCT ID NCT07057596
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 33 times
Summary
This study tests a drug called tebentafusp in people with a rare eye cancer (uveal melanoma) that has spread to the liver but not elsewhere. The goal is to see if giving the drug before surgery can completely destroy the liver tumors. About 19 participants will receive tebentafusp and then have their tumors checked or removed after 7 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MESTASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Charité - Universitätsmedizin Berlin
RECRUITINGBerlin, State of Berlin, 10117, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Consorcio Hospital General Universitario de Valencia
RECRUITINGValencia, Valencia, 46014, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital La Paz
RECRUITINGMadrid, Madrid, 28046, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Catala d'Oncologia (ICO) Hospitalet
NOT_YET_RECRUITINGL'Hospitalet de Llobregat, Barcelona, 08908, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.